The Global Alliance for TB Drug Development (TB Alliance) and sanofi-aventis announced that they have entered into a collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis (TB).

The TB Alliance is a not-for-profit, product development partnership, whose goal is the development of new TB drugs. The announcement was made at the 39th World Conference on Lung Health, organized by the International Union Against Tuberculosis and Lung Disease in Paris, France.

This collaboration agreement with the TB Alliance has been created to address the significant need to develop new TB drugs that will shorten treatment and be effective against drug-susceptible and drug-resistant strains of TB.

The TB Alliance, working with its public and private partners worldwide, is leading the development of the most comprehensive portfolio of TB drug candidates in history. It has two TB drug candidates in advanced clinical trials and 12 others in its pipeline.

Sanofi-aventis, which discovered rifampicin in the early 1960s, markets several anti-TB drugs. The company is also actively researching new therapeutic approaches for TB including new vaccines and drug candidates with new mechanisms of action.

Under the agreement, the two organizations will share information on their respective projects and exchange insights on developments in TB drug research. Additionally, they will consult with each other on relevant regulatory, access, and clinical trial capacity strategies related to developing countries. These activities may open new avenues of possible common development in the future.